By: Ana Elcarte
Algenex and Virbac sign an agreement for CrisBio®-based vaccine
22/02/2021Madrid (Spain) and Carros (France), February 22, 2021 – Algenex SL, a VC-backed biotechnology company delivering disruptive technologies for recombinant biologics... Read More
AskBio/Bayer Deal in the Top 10 largest Biopharma deals of 2020
25/01/2021January 2021- US - Fiercepharma rank the top 10 biopharma M&A deals announced in 2020 by deal value; Bayer's potentially $4... Read More
Almirall and Tyris Therapeutics develop next generation gene therapies
07/01/2021Barcelona / Valencia, January 2021.- Almirall, a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company... Read More
Aura Biosciences Appoints David Johnson to Its Board of Directors
05/01/2021CAMBRIDGE, Mass.--Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced... Read More
Vivet Therapeutics: FDA approved fase 1/2 study for VTX-801
19/11/2020PARIS / NEW YORK. November 2020 — Vivet Therapeutics, a gene therapy biotech company dedicated to developing treatments for inherited liver... Read More
Viralgen is awarded the “Radio San Sebastián Excellence Award”
17/11/2020San Sebastián. November 2020 - Viralgen was awarded the Radio San Sebastián Excellence Award at the Kursaal Congress Centre in San... Read More
Viralgen has received the DonostiaINN 2020 Award in San Sebastian
02/11/2020San Sebastián. Noviembre 2020 - Viralgen has received the DonostiaINN 2020 Award in the 'young innovative companies' category, from Fomento de... Read More
The 4 divestments from the Columbus VP Fund accumulate an IRR of 130%
28/10/2020Valencia | Madrid. October 2020 - Columbus Venture Partners, a Spanish-owned venture capital firm in the biotechnology sector, has announced the... Read More
Bayer boosts its gene therapy platform
28/10/2020San Sebastian, Spain. October 2020- The Basque company Viralgen, the first production site in Spain dedicated to the production of adeno-associated... Read More
Bayer acquires Asklepios BioPharmaceutical for $4 billion
26/10/2020Germany. October 2020- Bayer has struck a deal to acquire Asklepios BioPharmaceutical for $2 billion upfront. The deal, which features an... Read More